Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

The global canine arthritis treatment market is set for substantial expansion, projected to grow from an estimated USD 2.50 ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

Roche’s Elecsys pTau181 test has secured CE Mark approval, marking a development in ruling out Alzheimer's disease.

The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection Prevention, Could This Israeli Innovator Become Big Pharma’s Most Coveted Acquisition Target?